TVTXTravere Therapeutics, Inc.同业对比
Travere Therapeutics, Inc. 与SPDR S&P Biotech ETF 持仓的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:XBI 前十大持仓| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TVTX本股 | $6.1B#11 | — | 247.6x#14 | 12.4x#1 | 110.5%#3 | 92.1%#1 | -12.8%#1 | -104.2%#14 | — | — | 172.2%#8 | — |
| MRNA | $63.4B#1 | — | 9.4x#8 | 32.6x#3 | -39.9%#7 | 20.8%#6 | -158.1%#4 | -41.7%#11 | -54.6%#3 | — | 535.4%#4 | — |
| TWST | $9.8B#4 | — | 22.0x#12 | 26.1x#2 | 20.3%#5 | 62.8%#2 | -36.2%#2 | -17.4%#7 | -41.4%#2 | — | 480.1%#6 | — |
| ORKA | $6.3B#10 | — | 5.7x#3 | — | — | -25.9%#8 | — | -9.5%#4 | — | — | 490.3%#5 | — |
| KYMR | $9.9B#3 | — | 6.5x#6 | 251.8x#6 | -16.7%#6 | 39.1%#3 | -891.1%#6 | 20.6%#1 | — | — | 146.7%#10 | — |
| VKTX | $3.4B#14 | — | 8.4x#7 | — | — | -227.1%#15 | — | -88.1%#13 | — | — | — | — |
| PRAX | $8.6B#7 | — | 6.4x#4 | — | -100.0%#9 | -65.6%#11 | — | -22.6%#9 | — | — | 602.8%#2 | — |
| ERAS | $5.3B#13 | — | 14.7x#9 | — | — | 23.0%#5 | — | -34.4%#10 | — | — | 814.1%#1 | — |
| RVMD | $41.8B#2 | — | 16.1x#10 | — | — | -88.5%#13 | — | -43.4%#12 | — | — | 345.7%#7 | — |
| RYTM | $6.8B#8 | — | 66.3x#13 | 36.0x#4 | 45.8%#4 | 24.6%#4 | -101.2%#3 | -0.2%#3 | -133.8%#4 | — | 3.1%#14 | — |
| CGON | $6.7B#9 | — | 6.5x#5 | 1658.9x#7 | 254.7%#2 | -82.9%#12 | -4722.1%#7 | -15.6%#6 | -18.8%#1 | — | 100.6%#11 | — |
| SLS | $2.3B#15 | — | 16.9x#11 | — | -100.0%#9 | 13.0%#7 | — | -19.5%#8 | — | — | 580.2%#3 | — |
| PCVX | $9.0B#6 | — | 3.3x#1 | — | — | -65.2%#10 | — | -0.0%#2 | — | — | 95.7%#12 | — |
| DNTH | $5.6B#12 | — | 4.8x#2 | 2760.5x#8 | -67.3%#8 | -91.1%#14 | -8739.3%#8 | -13.9%#5 | — | — | 158.4%#9 | — |
| CYTK | $9.7B#5 | — | — | 110.4x#5 | 376.6%#1 | -33.2%#9 | -695.4%#5 | — | — | — | 47.2%#13 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-09-17。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议